US 11,708,349 B2
Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions
Alan Gill, Reading, MA (US); and Steven Perrin, Newbury, MA (US)
Assigned to ALS Therapy Development Institute, Cambridge, MA (US)
Appl. No. 16/982,923
Filed by ALS Therapy Development Institute, Cambridge, MA (US)
PCT Filed Feb. 15, 2019, PCT No. PCT/US2019/018161
§ 371(c)(1), (2) Date Sep. 21, 2020,
PCT Pub. No. WO2019/182698, PCT Pub. Date Sep. 26, 2019.
Claims priority of provisional application 62/646,112, filed on Mar. 21, 2018.
Prior Publication US 2021/0009558 A1, Jan. 14, 2021
Int. Cl. C07D 401/14 (2006.01); A61K 9/00 (2006.01); A61K 31/7072 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 9/0053 (2013.01); A61K 31/7072 (2013.01)] 13 Claims
 
1. A method comprising administering a compound of Formula (II) to a subject having a neurological disorder, wherein the compound of Formula (II) has the structure:

OG Complex Work Unit Chemistry
wherein R1 is H, R2 is H, R3 is H, R4 is H or null, R5 is —SR6, R6 is CH2(C3-6 cycloheteroalkyl), C3-6 cycloheteroalkyl, amino acid, amino acid derivative, C1-20 alkyl, or C1-20 heteroalkyl, A-B is C═CH, and D-E is CH—N or C═N; and
wherein the neurological disorder is amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease, Huntington's disease, prion-associated disease, spinocerebellar ataxia, or spinal muscular atrophy.